Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SynCardia makes Michael Garippa president

This article was originally published in Clinica

Executive Summary

Michael Garippa has become the president of SynCardia Systems, an artificial heart specialist. He will concentrate on aiding the firm’s sales, clinical support, training and marketing. Mr Garippa was previously the president and CEO of fellow cardiovascular company TandemHeart for eight years. SynCardia (Tucson, Arizona) sells the SynCardia temporary total artificial heart. The company says that there have been more than 850 implants of the device, which is approved by the US FDA and Health Canada, and has been CE marked for sale in Europe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel